Background. Although the brain-derived neurotrophic factor (BDNF) has been intensively investigated in animal models of chronic pain, its role in human pain processing is less understood.
Objective. To study the neurophysiology of BDNF modulation on acute experimental pain, we performed a cross-sectional study.
Methods. We recruited 20 healthy male volunteers (19-40 years old) and assessed their serum BDNF levels, quantitative sensory testing, and cortical excitability parameters using transcranial magnetic stimulation.
Results. Linear regression models demonstrated that the BDNF (b 5 25.245, P 5 0.034) and intracortical facilitation (b 5 -3.311, P 5 0.034) were inversely correlated with heat pain threshold (adjusted R 2 5 44.26). The BDNF (b 5 -3.719, P £ 0.001) was also inversely correlated with conditioned pain modulation (adjusted R 2 5 56.8).
Introduction
Pain-induced neuronal plasticity involves multiple molecular interactions [1, 2] , which notably include widespread neurotrophin brain-derived neurotrophic factor (BDNF), which is capable of strengthening excitatory (glutamatergic) synapses and weakening inhibitory (GABAergic) synapses [3] . BDNF production in the central nervous system (CNS) contributes to $80% of the circulating peripheral levels [4] . Given the important role of BDNF in modulating synaptic plasticity, this neurotrophic factor has been proposed as a marker to index neuroplasticity [5] . Indeed, BDNF presents different levels in patients with psychiatric diseases such as depression, anxiety, and schizophrenia [6] and changes after pharmacological and nonpharmacological interventions [7, 8] , which makes it appealing as a candidate marker for therapeutic responses. Nevertheless, BDNF is still scarcely explored in pain medicine. It is not clear whether BDNF is associated with increased or decreased nociceptive effects in animal models of neuropathic pain [9] , while animal models of inflammatory pain have suggested a sensitizing role of BDNF acting at cortical levels [10] . In humans, there is even less data to understand the role of BDNF in pain modulation. It is known that serum BDNF is correlated to psychophysical assessments that depend on sexual hormones [11, 12] , although the mechanisms involved in this response remain elusive.
To increase understanding of the neurophysiology of BDNF modulation on pain, different clinical research tools need to be combined. The primary motor cortex (M1) cortical excitability, assessed using transcranial magnetic stimulation (TMS), is another interesting candidate to index neuroplasticity. Although its initial description in the classic Penfield experiments attributed its name to its motor function, the role of M1 has been related to different neuronal circuits responsible for tasks beyond motor control in humans. M1 has been related to memory retrieval [13] , language processing [14] , and emotional processing [15] . Apart from the fact that its motor output is quantifiable, the M1 involvement with distant neural structures makes it a suitable candidate to explore neuromodulatory techniques [16, 17] . Thus, stimulation of the primary motor cortex has been widely explored for chronic pain syndromes [18] [19] [20] [21] [22] [23] . Although the mechanisms involved in this pain modulatory response are not clear yet [24, 25] , variable clinical effects have been shown, such as the age-dependent decline of conditioned pain modulation (CPM) and the impact of cognitiveemotional factors on the pain modulatory mechanisms [26] . Also, it is well known that females experience more pain than males in various pain states, and it has been demonstrated that in healthy subjects, higher levels of BDNF were correlated with higher pressure pain thresholds in females and and the inverse in males [12] .
Experimental pain thresholds are sensitive to sexual hormonal variations, and their relationship with BDNF is divergent (direct correlation in females, inverse for males). Thus, to avoid the risk of recruiting females in different hormonal phases (i.e., luteal vs follicular) and the potential confounding effect of the markedly cycling hormonal changes of women in contrast to the male sexual hormones with their divergent effect on BDNF, we recruited healthy male volunteers. We aimed to determine the relationship between BDNF serum levels and acute experimental pain response and to explore the neural substrates of this relationship by assessing transcranial magnetic stimulation-indexed cortical excitability and conditioned pain modulation. We hypothesize that BDNF would have an inverse relationship with the psychophysical pain tests, which could be related to the M1 cortical excitability.
Methods
The Methods and Results sections are reported according to STROBE guidelines [27] . All volunteers provided written informed consent prior to their participation in this study, and the protocol was approved by the Research Ethics Committee at the Hospital de Cl ınicas de Porto Alegre (HCPA; Institutional Review Board), according to the Declaration of Helsinki (Resolution 466/ 2012 of the National Health Council).
Study Design, Settings, and Participants
Volunteers were recruited by postings in universities, the Internet, and public places in the Porto Alegre area. Subjects were considered eligible if they were male, right-handed, and between 19 and 40 years old. Those with current acute or chronic pain conditions, the use of analgesics in the past week, a rheumatologic disease, a clinically significant or unstable medical or psychiatric disorder, a history of alcohol or substance abuse in the past six months, a neuropsychiatric comorbidity, or use of central nervous system-affecting medications were excluded. Also, those with any contraindications for TMS were also excluded [28] .
The volunteers were asked to abstain from alcohol and coffee consumption in the 24 hours preceding the test, and from drinking and eating six hours before starting the evaluation. After consenting, the volunteers started the evaluation undergoing a basic clinical assessment, in which they answered the questionnaires, and a blood sample was collected. Then, the cortical excitability parameters were determined, and after that the psychophysical pain testing (quantitative sensory testing) was performed.
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Sample Size Calculation
Considering that BDNF has been associated to pain threshold with an estimated Pearson correlation coefficient of 0.62 [12] , tolerating an alpha error of 0.05 and power of 0.90, a total sample size of 19 was estimated.
Because we further recruited 20 subjects and planned to study two dependent variables, a post hoc sample size calculation that considered dividing the alpha into these two variables (0.025) would still achieve a power of 85% [29] .
Dependent Variables
The psychophysical assessments included the heat pain threshold (HPT), defined as the minimal amount of temperature that evokes pain, and the pain reduction during a standard thermal stimulus while simultaneously receiving a heterotopic noxious stimulation (CPM).
Quantitative Sensory Testing
The method of limits with a computer Peltier-based device thermode (30Â30 mm) was used to assess HPT [30] . The thermode was attached to the skin on the ventral aspect of the midforearm, and the temperature was increased at a rate of 1 C/sec, from 30 C to a maximum of 52 C, which primarily stimulates C-nociceptive afferents [31] . Female researchers performed all the quantitative sensory testing assessments. Participants were asked to press a button as soon as the sensation of heat began at the heat detection threshold and as soon as the stimulation became painful (HPT). A single training session was offered so that participants could get familiar with the device. An average of three assessments for each threshold test was considered (interstimulus interval of 40 seconds, each one with a slight repositioning of the thermode to avoid the sensitization of skin receptors) [32] . If 52 C was achieved before reporting pain, the device cooled down automatically, and the pain threshold was considered unknown.
The CPM activates the diffuse noxious inhibitory control-like effect because it is a strong nociceptive stimulus over a lengthy span of time [33] and a large body surface area [32] . The CPM consists of a conditioning and test stimulus. The test stimulus was the temperature to be used during the CPM, in which subjects were asked to stop the temperature rise when experiencing a pain intensity of 6 (HPT60, in C) on the numerical rating scale (from 0 to 10; NRS 0-10 ). The conditioning stimulus was intense pain induced by cold. It was achieved by immersing the nondominant hand in cold water (zero to 1 C) for at least one minute. The CPM was induced by simultaneously applying the test stimulus temperature (HPT60) on the right forearm (dominant forearm) and the immersing the left hand in cold water. Then, that same temperature was applied, and subjects were asked to rate their pain on the NRS 0-10 (NRS 0-10 before CPM). Subjects were asked to rate their pain in the dominant forearm again (NRS 0-10 during CPM). The CPM was calculated by subtracting the NRS 0-10 "during" from "before" CPM (CPM ¼ before-during) [34] . Each CPM paradigm was repeated three times (with short intervals between them) for each evaluation, and their mean was considered for the final analysis.
Independent Variables

Cortical Excitability-Transcranial Magnetic Stimulation
The cortical excitability parameters were transcranial magnetic stimulation (TMS)-indexed intracortical facilitation (ICF), short intracortical inhibition (SICI), cortical silent period (CSP), and motor-evoked potential (MEP). TMS of the left motor cortex (M1) was performed using a MagPro X100 stimulator (MagVenture Company, Lucernemarken, Denmark) through a figure-eight coil (MagVenture Company). The coil was placed tangentially to the scalp over the left M1, with an angle of 45 to the sagittal line to identify the motor "hot spot." The "hot spot" is the coil position in which the lowest motor threshold (MT) intensity was required to elicit an acceptable response in at least 50% of the evoked potentials of the resting first dorsal interosseus (FDI) [35] . The "hot spot" was marked with a soft-tipped pen to ensure a constant placement of the coil throughout the experiment. First, the motor threshold was defined as the lowest stimulus intensity sufficient to elicit a response of at least five of 10 evoked potentials with a minimum amplitude of 50 mV in the resting FDI [35] . Then, single-pulse measures, including the MEP and CSP, were recorded at an intensity of 130% of the MT. The MEP value was the mean of 10 consecutive trials with a minimum amplitude peak-to-peak of 1 mV. To assess the CSP, subjects were instructed to perform isometric contractions of the FDI with approximately 10% of the maximal force. The CSP was considered the transient silence in isometric voluntary EMG activity preceded by the MEP [35] . A mean of 10 consecutive trials was considered for each subject. To assess the SICI (interstimulus interval of 2 ms) and the ICF (interstimulus interval of 12 ms), the first subthreshold stimulus was set at 80% of the MT, and the second suprathreshold stimulus was set at 130%. Thirty recordings (10 for each SICI, ICF, and test stimuli) were made in random order with an interval of eight seconds between each pulse. Paired-pulse measures were analyzed by calculating their individual indexes (mean SICI/mean test stimuli; mean ICF/mean of test stimulus). The same MT value was used to elicit the MEP, CSP, SICI, and ICF. To reduce the variability, the same researcher performed all TMS assessments. The values used to analyze cortical responses are ratios to the MEP, i.e., SICI/MEP and ICF/MEP.
Serum Brain-Derived Neurotrophic Factor
The serum BDNF concentration was determined using an enzyme-linked immunosorbent assay (ELISA) kit (Chemicon/Millipore, catalog No. CYT306, lower detection limit of the kit ¼ 7.8 pg/mL), according to the manufacturers' instructions. Samples were gathered in plastic tubes and centrifuged for 10 minutes at 4,500 rpm and 4 C. The serum was frozen at À80 C until assays were performed.
Demographic and Psychological Profile
Pain catastrophizing thinking was assessed using the validated Brazilian-Pain Catastrophizing Scale (B-PCS) [36] . Depression symptoms were screened using the Beck Depression Inventory (BDI) [37] . Demographic data were gathered using a standardized questionnaire. Anxiety was measured with the State-Trait Anxiety Inventory (STAI), adapted to Brazilian Portuguese [38] . State anxiety (a situation-driven transient anxiety) and trait anxiety (stable personality disposition reflecting general level of fearfulness) were evaluated. Higher scores denote higher levels of anxiety.
Statistical Analyses
Conventional descriptive statistics were used to summarize the main features of the sample. The normality was tested using Kolmogorov-Smirnov tests. After verifying the corresponding assumptions, the following variables were log-transformed to allow parametrical handling: STAI, B-PCS, BDNF, SICI, ICF, MEP. Further, independent linear regression analysis models using the best subsets method were used [39] to identify the possible clinical and cortical excitability parameters (ICF, SICI, CSP) associated to the dependent variables (HPT and pain during CPM) independently. The MEP alone was not included in the linear regression models because other outcomes are derived using it, which would violate the assumption of independency between variables. Bonferroni's correction was performed to account for multiple comparisons. Thus, given that regression models were performed for two dependent variables (HPT and CPM), the alpha value considered significant was 0.025. The analyses were performed using SPSS version 20.0 (IBM SPSS Statistics for Windows, version 20.0; IBM Corp., Armonk, NY, USA).
Results
Twenty-two participants were included, and the two participants reporting a BDI higher than 12 were excluded. Participants' clinical and psychophysical testing and cortical excitability characteristics are summarized in Table 1 .
To assess the clinical and cortical excitability parameters capable of predicting the HPT, a best subset linear modeling was performed. The ICF, the BDNF, and the age provided the best linear model, moderately explaining the variability of the HPT (adjusted R 2 ¼ 44.26) (see Table 2 ). For illustrative purposes, a scatterplot of the raw HPT and BDNF is presented in Figure 1 , and a scatterplot of the HPT and ICF is presented in Figure 2 . Summarizing, both ICF and BDNF were independently and inversely correlated with the HPT. This indicates that those with lower tolerance presented higher facilitation when holding BDNF constant, or higher serum BDNF levels if assuming constant ICF.
The association of the independent variables to the CPM was explored using the same approach. The BDNF alone provided the best linear model, moderately explaining the variability of the CPM (adjusted R 2 ¼ 56.8) (see Table 3 ). For illustrative purposes, a scatterplot of the raw CPM and BDNF is presented in Figure 3 . Briefly, the BDNF was independently and inversely correlated to the CPM, suggesting that those with less descending pain inhibition (lower CPM) had higher serum BDNF levels. 
Discussion
Our findings highlight that the serum BDNF level is inversely correlated with either the loss of endogenous inhibitory control or an enhancement of pain facilitation. Additionally, it is negatively correlated with the HPT. All the correlations moderately explained the outcomes of interest, which is relevant when considering biological and psychophysical variables. Taken together, these results support that in healthy male volunteers serum BDNF increases heat nociception and descending pain inhibition, possibly by mechanisms involving glutamatergic pathways, as suggested by the association of M1 intracortical facilitation and the pain response.
Although the underlying mechanisms of BDNF modulation in nociception are not completely clear, in vitro, in vivo, and clinical studies provide relevant insights to help in the interpretation of our results. In vitro studies showed that neuronal activity induced BDNF production, favoring the activity of inhibitory networks, whereas reduced neuronal activity was accompanied by decreased BDNF production and increased excitability [40, 41] . Animal studies have shown that the expression of the Cl À -cotransporter K þ -Cl À exporter (KCC2) in the dorsal horn is reduced by BDNF, increasing the intracellular chloride that reduces GABA ability to inhibit nociception [2] . BDNF also promotes neuronal plasticity in the anterior cingulate cortex, and it is necessary for induction of neuronal hyperexcitability, the emergence of cold hypersensitivity, and the passive avoidance behavior appearance after inflammatory pain [10] . Because the BDNF is produced in the central nervous system, and later transported through the brain-blood barrier to the vascular compartment [4] , it is reasonable to make inferences based on the serum BDNF.
Due to the demonstrated role of BDNF in spinal cord sensitization in animal experiments, clinical studies have been developed trying to elucidate the extent of these inferences to humans. Our experiment shows an inverse correlation between serum BDNF and the HPT in healthy male volunteers, which is in agreement with previous descriptions showing that serum BDNF is inversely correlated to PPT in healthy volunteers [12] and in fibromyalgia patients [42] . Such correlation could be explained according to the mechanisms of BDNF described in animals. Furthermore, because of this inverse correlation with pain thresholds in the healthy and the diseased, it has been proposed that serum BDNF could have a role aiding in the characterization of central sensitization syndromes [5] .
Our sample presented a CPM effect consistent with literature reports [43] , which was also inversely correlated with serum BDNF. Interestingly, such inverse correlation is also present in patients with fibromyalgia [42] , which speaks in favor of the hypothesized "sensitizing" role of BDNF in human pain modulation, as has been described in animals. The mechanisms of the CPM involve multiple neuronal structures, from spinal cord dorsal horn, medullary nucleus reticularis dorsalis, and periaqueductal gray matter to cortical areas such as prefrontal, anterior cingulate, and insular [44] [45] [46] [47] . CPM integrity also requires serotonergic and noradrenergic neurotransmission [48] [49] [50] . Thus, BDNF might have an effect on pain modulation in any of these circuits, while at the same time it might hypothetically be susceptible to modulation by different therapeutic interventions. For example, it has been recently shown that stimulation of the primary motor cortex using repetitive TMS in patients with chronic myofascial pain syndrome is capable of improving the CPM, which was related to modulation of the serum BDNF [8] . Unfortunately, because of the complex nature of the CPM response, current clinical research techniques are not capable of assessing all the potential circuits and neuronal areas involved in this intriguing physiological response.
The use of paired-pulse TMS in our experimental design allowed us to assess cortical and subcortical responses. The excitability of the primary motor cortex has been used as a gross surrogate of some neuronal circuits because of its accessibility with this technique. In our sample, we observed an inverse correlation between the ICF and the HPT. The ICF is originated by excitatory postsynaptic potentials [51] mainly mediated by glutamatergic NMDA synaptic transmission [52, 35] . The ICF can be inhibited by the use of NMDA receptor antagonists (i.e., dextromethorphan) [53] , decreased by GABA-A agonists (e.g., Lorazepam) and barbiturates, and increased by GABA-B agonists (e.g., Baclofen) [54] . Conceptualizing the nociception as the response of a dynamic physiological system, it is plausible to hypothesize that the inverse correlation between the ICF and the HPT that we observed in our experiment could reflect a system that has a higher excitatory tone in comparison with the inhibitory load, thus favoring a facilitatory pain response. Such balance that favors facilitation would be translated into lower pain thresholds. Higher Cortical Facilitation and Serum BDNF Likewise, it is possible that increased BDNF levels reflecting increased M1 plasticity would thus decrease pain processing and also homeostatically decrease activation of M1, as reflected by decreased ICF. The primary motor cortex, the main area of assessment for TMS excitability, could be used as a neural target to assess pain-related cortical neuroplasticity. It has been demonstrated that the stimulation of M1 reduces pain-related responses in the somatosensory cortex [55, 56] , and it modulates intracortical inhibitory processes [56] [57] [58] .
The design of our study implies relevant limitations. The cross-sectional study design does not enable us to determine the temporal relationship or cause-effect relationships between serum BDNF secretion, glutamatergic activity, and pain threshold. Further experimental designs are still required in order to determine causality. Female examiners applied the psychophysical pain testing to healthy male volunteers in our study. Although gender could have an influence in quantitative sensory testing, the fact that all examiners were female reduces the chances of inducing variability. Also, relevant considerations should be made because our experiment included males only. Previous reports have demonstrated that pain thresholds are correlated to BDNF in a divergent manner regarding sex, as females' thresholds are proportional to BDNF, while in males the correlation is the inverse [12] . Also, women present cyclic hormonal changes that consistently modulate cortical excitability, having increased cortical inhibition (assessed by TMS) during the luteal phase in comparison with the follicular phase [59] . Given this, the authors strongly suggest against extending the findings of our experiment to the female population.
Overall, these findings suggest that in healthy males, serum BDNF is correlated with pain processing, corroborating its modulatory role in the excitatory/inhibitory balance in the CNS [60, 61] . These findings might have important clinical implications in the advancement of the lab-to-clinic study of pain modulation and treatment. Although we aimed to understand further the neural basis of the relationship between BDNF and pain modulation, the technique we used to assess cortical plasticity-TMS-although reliable, can only assess motor cortex excitability. Further studies should also use other neurophysiological tools.
